Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Retreatment with interferon-alpha at dosages or period increased by 1.3 times is effective for treatment for transient responders and non-responders in chronic hepatitis C patients
Autore:
Okanoue, T; Daimon, Y; Kirishima, T; Ohnishi, N; Nakamura, H; Nagao, Y; Minami, M; Itoh, Y;
Indirizzi:
Kyoto Prefectural Univ Med, Dept Internal Med 3, Kamigyo Ku, Kyoto 6028566, Japan Kyoto Prefectural Univ Med Kyoto Japan 6028566 Ku, Kyoto 6028566, Japan
Titolo Testata:
HEPATOLOGY RESEARCH
fascicolo: 3, volume: 20, anno: 2001,
pagine: 348 - 358
SICI:
1386-6346(200107)20:3<348:RWIADO>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
HEPATOCELLULAR-CARCINOMA; INITIAL COURSE; THERAPY; VIRUS; NONRESPONDERS; RIBAVIRIN; RISK;
Keywords:
chronic hepatitis C; interferon; retreatment; complete response; transient response;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
17
Recensione:
Indirizzi per estratti:
Indirizzo: Okanoue, T Kyoto Prefectural Univ Med, Dept Internal Med 3, Kamigyo Ku, Kyoto 6028566, Japan Kyoto Prefectural Univ Med Kyoto Japan 6028566 6028566, Japan
Citazione:
T. Okanoue et al., "Retreatment with interferon-alpha at dosages or period increased by 1.3 times is effective for treatment for transient responders and non-responders in chronic hepatitis C patients", HEPATOL RES, 20(3), 2001, pp. 348-358

Abstract

The objectives of retreatment with interferon (IFN) in chronic hepatitis C(CH-C) patients are sustained response and a reduction in the risk of hepatocellular carcinoma (HCC). However, it is still unclear, as to which patients are candidates for retreatment with IFN. Eighteen transient responders (TRs) and 15 non-responders (NRs) to IFN therapy in Cl-I-C received retreatment with IFN alpha. Of the 18 TRs, five showed sustained disappearance of hepatitis C virus, two showed sustained biochemical response, 10 continued as TR and one was a NR. Of the 15 NRs, six showed a TR while nine continuedas NRs. Responsive cases, which included the virologically or biochemically sustained and transient responders, received either a dose of IFN 1.3 times greater or were treated for a period of 1.3 times longer in the retreatment than the original treatment. We submit that IFN treatment consisting ofeither a time period or a dosage 1.3 times those of the original IFN administration may he beneficial in the case of TR and NR in chronic hepatitis Cpatients. (C) 2001 Elsevier Science B.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/09/20 alle ore 21:53:47